Categories
Change Password!
Reset Password!
With potent TSLP neutralization and extended half-life, TAVO101 (a novel anti-TSLP antibody) appears to be a promising therapeutic candidate for TSLP-driven diseases.
A novel breakthrough in immunotherapy could redefine treatment for allergic inflammation, chronic inflammatory diseases, autoimmune disorders, and cancers. Researchers have developed TAVO101, a novel humanized anti-thymic stromal lymphopoietin (TSLP) antibody designed to neutralize excessive TSLP activity, a key driver of allergic inflammation against pathogenic microbes at barrier surfaces of the gut, skin, and lung.
TAVO101 exhibits high binding affinity to human TSLP, effectively blocking TSLP from binding to its receptor complexes on cell surfaces. In functional assays, TAVO101 illustrated potent neutralization of TSLP-driven signal transducer and activator of transcription (STAT5) activation and cell proliferation, confirming its ability to suppress inflammatory pathways. Ex vivo studies illustrated that TAVO101 inhibited TSLP-mediated C-C chemokine ligand 17 (CCL17) release from primary human CD1c+ dendritic cells and suppressed the proliferation of activated CD4+ T cells—two key processes in allergic inflammation.
In preclinical models, TAVO101 displayed robust effectiveness in both TSLP/ovalbumin (OVA)-triggered asthma and imiquimod-triggered psoriasis in humanized knock-in mice expressing human TSLP and its receptor. To optimize its clinical potential, researchers engineered TAVO101’s Fc region to:
By targeting a distinct TSLP epitope and demonstrating comparable potency to tezepelumab with an extended circulating half-life, TAVO101 represents a promising next-generation biologic for asthma, psoriasis, and other TSLP-mediated diseases.
Frontiers in Immunology
A novel monoclonal antibody against human thymic stromal lymphopoietin for the treatment of TSLP-mediated diseases
Lihua Shi et al.
Comments (0)